Cargando…

Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors

BACKGROUND: The success of immune checkpoint inhibitors has revolutionized cancer treatment options and triggered development of new complementary immunotherapeutic strategies, including T-cell co-stimulatory molecules, such as glucocorticoid-induced tumor necrosis factor receptor-related protein (G...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, R., Baxi, V., Li, Z., Locke, D., Hedvat, C., Sun, Y., Walsh, A.M., Shao, X., Basavanhally, T., Greenawalt, D.M., Patah, P., Novosiadly, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163007/ https://www.ncbi.nlm.nih.gov/pubmed/36863094 http://dx.doi.org/10.1016/j.esmoop.2023.100784

Ejemplares similares

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
por: Rottey, Sylvie, et al.
Publicado: (2022)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
por: Lee, Sun Ku, et al.
Publicado: (2017)

Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529
por: Pancera, Marie, et al.
Publicado: (2017)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Dissociated Agonist of Glucocorticoid Receptor or Prednisone for Active Rheumatoid Arthritis: Effects on P1NP and Osteocalcin Pharmacodynamics
por: Shoji, S, et al.
Publicado: (2017)

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
por: Callahan, Margaret K, et al.
Publicado: (2013)

Construction of the MPI BMS Prototype Chamber
por: Bratzler, U, et al.
Publicado: (1997)

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
por: Postow, Michael A, et al.
Publicado: (2014)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

BMS1 Is Mutated in Aplasia Cutis Congenita
por: Marneros, Alexander G.
Publicado: (2013)

Safety, Pharmacokinetics, and Pharmacodynamics of CC‐90001 (BMS‐986360), a c‐Jun N‐terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants
por: Ye, Ying, et al.
Publicado: (2022)

The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia
por: Bristow, Linda J., et al.
Publicado: (2016)

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis
por: Serritella, Anthony V., et al.
Publicado: (2023)

Role of Mitochondrial Toxicity in BMS-986094-Induced Toxicity
por: Feng, Joy Y., et al.
Publicado: (2017)

Effect of BMS-470539 on lipopolysaccharide-induced neutrophil activation
por: Lee, Seongheon, et al.
Publicado: (2020)

In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure
por: Gargalovic, Peter, et al.
Publicado: (2021)

Pharmacodynamic analysis of an agonistic antibody to the costimulatory receptor GITR
por: Moody, Gordon, et al.
Publicado: (2015)

Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants
por: Catlett, Ian M., et al.
Publicado: (2020)

DNA methylation as a pharmacodynamic marker of glucocorticoid response and glioma survival
por: Wiencke, J. K., et al.
Publicado: (2022)

Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning
por: Weed, Michael R., et al.
Publicado: (2017)

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
por: Yap, Timothy A., et al.
Publicado: (2022)

Phase I study of the mitomycin C analogue BMS-181174.
por: Macaulay, V. M., et al.
Publicado: (1998)

Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780
por: Toyn, Jeremy H., et al.
Publicado: (2014)

A Behaviour Monitoring System (BMS) for Ambient Assisted Living
por: Eisa, Samih, et al.
Publicado: (2017)

The effects of BMS-470539 on lipopolysaccharide-induced acute lung injury
por: Jang, Eun-A, et al.
Publicado: (2019)

BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study
por: Chu, Quincy, et al.
Publicado: (2022)

First‐in‐human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects
por: Perera, Vidya, et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates
por: Devalaraja-Narashimha, Kishor, et al.
Publicado: (2022)

An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists
por: Chen, Xia, et al.
Publicado: (2012)

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review
por: van Bussel, Mark T. J., et al.
Publicado: (2019)

The Effectiveness and Adverse Events of Amitriptyline and Aripiprazole in Very Elderly Patients With BMS
por: Watanabe, Motoko, et al.
Publicado: (2022)

An Unexpected Mode Of Binding Defines BMS948 as A Full Retinoic Acid Receptor β (RARβ, NR1B2) Selective Agonist
por: Nadendla, Eswarkumar, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hidr9u4mu2o8ghb5jhu4fai7kk